Arizona is currently home to 1697 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Phoenix, Tucson, Scottsdale and Mesa. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
NCT05184335
Recruiting
This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg or 50 mg once daily over 4 weeks, then in the long-term flexible doses 15-50mg daily over a period of 52 weeks.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
12/16/2024
Locations: Reviva site, Phoenix, Arizona
Conditions: Schizophrenia
Register for Updates
A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer
NCT04831580
Recruiting
This is a randomized controlled trial to compare survival for patients who undergoe robotic assisted laparoscopy versus open hysterectomy and lymph node assessment for the treatment of early stage cervical cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/16/2024
Locations: Western Regional Medical Center LLC, Goodyear, Arizona
Conditions: Cervical Cancer
Register for Updates
Working Memory Training in Patients with Mild Cognitive Impairment
NCT06734286
Recruiting
The purpose of this study is to test whether a special memory training program, called CogMed, can help people with early memory problems. The Investigators want to see if this training improves memory and also helps reduce stress. The Investigators also want to see if CogMed results in changes to a blood biomarker called p-Tau 217, which possibly indicate Alzheimer's disease (AD).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
12/12/2024
Locations: Barrow Neurological Institute, Division of Alzheimer's Disease, Phoenix, Arizona
Conditions: Mild Cognitive Impairment (MCI)
Register for Updates
Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years
NCT05643534
Recruiting
This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of tenapanor (25 mg and 50 mg) in pediatric patients (≥12 and \<18 years old) with IBS-C when administered twice daily (BID) for 12 consecutive weeks.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
12/12/2024
Locations: Eclipse Clinical Research, Tucson, Arizona
Conditions: Irritable Bowel Syndrome With Constipation (IBS-C)
Register for Updates
RESTORE: An RCT to Evaluate the Efficacy of the Revi System
NCT06217328
Recruiting
The Revi System is indicated for the treatment of patients with symptoms of urgency incontinence alone or in combination with urinary urgency.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
12/11/2024
Locations: Arizona Urology Specialists, Tucson, Arizona
Conditions: Urinary Urge Incontinence
Register for Updates
ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)
NCT05388708
Recruiting
ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives. The first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatr... Read More
Gender:
ALL
Ages:
Between 14 days and 20 years
Trial Updated:
12/11/2024
Locations: Phoenix Children's Hospital, Phoenix, Arizona
Conditions: Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation
Register for Updates
Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
NCT03715933
Recruiting
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
12/09/2024
Locations: HonorHealth Research Institute, Scottsdale, Arizona
Conditions: Colorectal Adenocarcinoma, Ewing Sarcoma
Register for Updates
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT04300556
Recruiting
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer \[OC\], endometrial cancer \[EC\], non-small cell lung carcinoma \[NSCLC\], triple-negative breast cancer \[TNBC\]), and (2) in dose-confirmation part: to evaluate preliminary efficacy measured by objective response rate (ORR) of farletuzu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Arizona Clinical Research Center - Hunt - PPDS, Tucson, Arizona
Conditions: Solid Tumor
Register for Updates
A Vaccine (VSV-hIFNβ-NIS) with or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
NCT03017820
Recruiting
This phase I trial studies the best dose and side effects of the VSV-hIFNβ-NIS vaccine with or without cyclophosphamide and combinations of ipilimumab, nivolumab, and cemiplimab in treating patients with multiple myeloma, acute myeloid leukemia or lymphoma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). VSV-IFNβ-NIS is a modified version of the vesicular stomatitis virus (also called VSV). This virus can cause infection and when it... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-cell Lymphoma, Recurrent Mycosis Fungoides, Recurrent Plasma Cell Myeloma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Plasma Cell Myeloma, Refractory T-Cell Non-Hodgkin Lymphoma, Myelodysplastic Syndrome, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Acute Myeloid Leukemia, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm
Register for Updates
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
NCT06508463
Recruiting
This phase I trial studies the best dose and side effects of recombinant vesicular stomatitis virus (VSV) carrying the human (h) sodium iodide symporter (NIS) and Interferon (IFN) beta (β) genes (VSV-hIFNβ-NIS) in combination with ipilimumab and cemiplimab in patients with T-cell lymphoma. A virus, called VSV-hIFNβ-NIS, which has been changed in a certain way, may be able to kill cancer cells without damaging normal cells. Immunotherapy with ipilmumab and cemiplimab may induce changes in body's... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Relapsed Anaplastic Large Cell Lymphoma, Relapsed Mycosis Fungoides
Register for Updates
The TELENEO Trial: a Multicenter Trial of Telemedicine for Advanced Neonatal Resuscitations in Community Hospitals
NCT06087224
Recruiting
The purpose of this study is to evaluate the impact of real-time audio-video telemedicine consults with a neonatologist (termed teleneonatology) on the early health outcomes of at-risk neonates delivered in community hospitals.
Gender:
ALL
Ages:
0 days and above
Trial Updated:
12/05/2024
Locations: Mayo Clinic Arizona, Pheonix, Arizona
Conditions: Death; Neonatal, Morbidity;Newborn
Register for Updates
Stroke Thrombectomy and Aneurysm Registry
NCT04994756
Recruiting
This international multi-center registry is used to collect existing information and outcomes for patients undergoing an operation for treatment of injuries to the brain including the blockage of blood flow to an area of the brain, an abnormal ballooning of an artery, abnormal tangling of blood vessels, abnormal formation of blood vessels, tearing of vein, and bleeding in the brain. This information is used to help predict outcomes that undergo an operation for treatment of the above-listed brai... Read More
Gender:
ALL
Ages:
Between 1 year and 120 years
Trial Updated:
12/05/2024
Locations: University of Arizona, Tucson, Arizona
Conditions: Stroke, Thromboses, Intracranial, Aneurysm, Brain
Register for Updates